Zelandopam free base | MYD-37; | YM-435 | CAS#139233-53-7 | dopamine D1 agonist

MedKoo Cat#: 328084 | Name: Zelandopam free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Zelandopam, also known as MYD-37; YM-435, is a dopamine D1 agonist potentially for the treatment of heart failure and hypertension. YM435 is a potent stimulant of pancreatic exocrine secretion by acting on DA D1 receptors of the pancreas in dogs. Intravenous administration of YM435 produces renal vasodilating and diuretic/natriuretic effects by stimulation of dopamine D1 receptors, and demonstrate that YM435 can inhibit angiotensin II-, renal nerve stimulation- and PAF-induced renal dysfunction.

Chemical Structure

Zelandopam free base

CAS#139233-53-7

Theoretical Analysis

MedKoo Cat#: 328084

Name: Zelandopam free base

CAS#: 139233-53-7

Chemical Formula: C15H15NO4

Exact Mass: 273.1001

Molecular Weight: 273.29

Elemental Analysis: C, 65.92; H, 5.53; N, 5.13; O, 23.42

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Zelandopam; MYD-37; YM-435; MYD37; YM435.

IUPAC/Chemical Name

(S)-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline-7,8-diol

InChi Key

FULLEMQICAKPOE-JTQLQIEISA-N

InChi Code

InChI=1S/C15H15NO4/c17-12-3-1-8(5-14(12)19)10-6-16-7-11-9(10)2-4-13(18)15(11)20/h1-5,10,16-20H,6-7H2/t10-/m0/s1

SMILES Code

OC1=C(O)C2=C(C=C1)[C@H](C3=CC=C(O)C(O)=C3)CNC2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 273.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Yatsu T, Aoki M, Tanaka A. Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats. Eur J Pharmacol. 2005 Mar 7;510(1-2):121-6. PubMed PMID: 15740732. 2: Yatsu T, Aoki M, Inagaki O. Preventive effect of zelandopam, a dopamine D1 receptor agonist, on cisplatin-induced acute renal failure in rats. Eur J Pharmacol. 2003 Feb 14;461(2-3):191-5. PubMed PMID: 12586214. 3: Yasunari K, Kohno M, Kano H, Hanehira T, Minami M, Yoshikawa J. Anti-atherosclerotic action of vascular D1 receptors. Clin Exp Pharmacol Physiol Suppl. 1999 Apr;26:S36-40. Review. PubMed PMID: 10386252. 4: Yatsu T, Arai Y, Takizawa K, Kasai-Nakagawa C, Takanashi M, Uchida W, Inagaki O, Tanaka A, Takenaka T. Effect of YM435, a dopamine DA1 receptor agonist, in a canine model of ischemic acute renal failure. Gen Pharmacol. 1998 Nov;31(5):803-7. PubMed PMID: 9809482. 5: Yatsu T, Arai Y, Sudoh K, Shibasaki M, Uchida W, Inagaki O, Tanaka A, Takenaka T. Effect of YM435, a novel dopamine DA1 receptor agonist, in a canine model of acute congestive heart failure. Gen Pharmacol. 1998 May;30(5):733-7. PubMed PMID: 9559326. 6: Yasunari K, Kohno M, Hasuma T, Horio T, Kano H, Yokokawa K, Minami M, Yoshikawa J. Dopamine as a novel antimigration and antiproliferative factor of vascular smooth muscle cells through dopamine D1-like receptors. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3164-73. PubMed PMID: 9409307. 7: Yatsu T, Miyamoto I, Kaneko-Takanuki F, Watanabe T, Takenaka T. Pharmacological and pharmacokinetic characteristics of YM435, a novel dopamine DA1-receptor agonist, in anaesthetized dogs. J Pharm Pharmacol. 1997 Sep;49(9):892-6. PubMed PMID: 9306257. 8: Yatsu T, Uchida W, Inagaki O, Tanaka A, Takenaka T. Dopamine DA1 receptor agonist activity of YM435 in the canine renal vasculature. Gen Pharmacol. 1997 Aug;29(2):229-32. PubMed PMID: 9251904. 9: Yatsu T, Arai Y, Takizawa K, Kasai-Nakagawa C, Takanashi M, Uchida W, Inagaki O, Tanaka A, Asano M, Honda K, Takenaka T. Renal effect of YM435, a new dopamine D1 receptor agonist, in anesthetized dogs. Eur J Pharmacol. 1997 Mar 12;322(1):45-53. PubMed PMID: 9088869. 10: Yatsu T, Takizawa K, Kasai-Nakagawa C, Uchida W, Tanaka A, Asano M, Honda K, Takenaka T. Hemodynamic characterization of YM435, a novel dopamine DA1 receptor agonist, in anesthetized dogs. J Cardiovasc Pharmacol. 1997 Mar;29(3):382-8. PubMed PMID: 9125677. 11: Yasunari K, Kohno M, Kano H, Yokokawa K, Minami M, Yoshikawa J. Dopamine D1-like receptor stimulation inhibits hypertrophy induced by platelet-derived growth factor in cultured rat renal vascular smooth muscle cells. Hypertension. 1997 Jan;29(1 Pt 2):350-5. PubMed PMID: 9039126. 12: Anan H, Tanaka A, Tsuzuki R, Yokota M, Yatsu T, Fujikura T. 4-(3,4-Dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives. II. Their renal vasodilation activity and structure-activity relationship. Chem Pharm Bull (Tokyo). 1996 Oct;44(10):1865-70. PubMed PMID: 8904813. 13: Iwatsuki K, Horiuchi A, Ren LM, Chiba S. D-1 dopamine receptors mediate dopamine-induced pancreatic exocrine secretion in anesthetized dogs. Hypertens Res. 1995 Jun;18 Suppl 1:S173-4. PubMed PMID: 8529053. 14: Ofori S, De Raad S, Bugnon O, Schorderet M. Effects of YM 435 and A 77636 on dopamine D-1 receptors in bovine retina in vitro. Gen Pharmacol. 1995 Jan;26(1):51-7. PubMed PMID: 7713366. 15: Takenaka T, Forster H, Epstein M. Characterization of the renal microvascular actions of a new dopaminergic (DA1) agonist, YM435. J Pharmacol Exp Ther. 1993 Mar;264(3):1154-9. PubMed PMID: 8095547. 16: Iwatsuki K, Ren LM, Chiba S. Effects of YM435, a novel dopamine D1 receptor agonist, on pancreatic exocrine secretion in anesthetized dogs. Eur J Pharmacol. 1992 Aug 6;218(2-3):237-41. PubMed PMID: 1425944. 17: Anan H, Tanaka A, Tsuzuki R, Yokota M, Yatsu T, Honda K, Asano M, Fujita S, Furuya T, Fujikura T. Synthesis, resolution, and renal vasodilation activity of novel DA1 agonists: 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives. Chem Pharm Bull (Tokyo). 1991 Nov;39(11):2910-4. PubMed PMID: 1839245.